Seagen, Astellas Data Support Broader Indication For Padcev/Keytruda Combo

Data May Facilitate Closing Of Pfizer Merger

 
• By Joseph Haas

With accelerated approval in advanced urothelial cancer, the sponsors now have data that could support full approval.

Antibody-drug conjugate
Seagen/Astellas's Padcev might now be appropriate treatment in more bladder cancer patients • Source: Shutterstock

More from Clinical Trials

More from R&D